AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)

Recruitingn/aAges 20 Years - 120 YearsAllNational Institute on Aging (NIA)
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Background: \- Biomarkers are substances in people's blood and tissues. They help researchers understand diseases and signs of aging. Scientists want to do more research on biomarkers to find ways to improve quality of life in old age. Objective: \- To learn more about biomarkers and their relationship to aging. Eligibility: \- Adults at least 20 years old who weigh at least 110 pounds and have a body mass index below 30. They must agree that their genetic samples can be collected, studied, and stored. Design: * Participants will be screened with medical history, physical exam, EKG and blood and urine tests. * Participants will have 3-day visits. They will return every 2 years. * All visits include: * Blood and urine collection * Physical performance tests * Health questionnaires * Memory and problem-solving tests * Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT)

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
* Since the study of gene expression and epigenetic regulation are essential aims of GESTALT, all participants are required to consent to DNA/RNA testing and storage at all visits. Participants that refuse genetic testing and storage will not be eligible to participate or to continue to participate in the study. The criteria below for each group pertains only to the Screening and Baseline Visits, except where otherwise noted. If any of the conditions develop while the participant is in the study, the participant remains in the study. However, participants that develop severe cognitive problems and are diagnosed by the cognition group with dementia, will no longer be able to participate in the study. INCLUSION CRITERIA for the Healthy Group: * Age \>= 20 years of age. * Are willing to return every 2 years for study visit procedures. * Agree to genetic (DNA/RNA) sample collection, analysis, and storage. * Have good venous access for cytapheresis and are in good health as determined by the Apheresis Health History Questionnaire and are found eligible for apheresis (Apheresis Eligibility form). * Weigh \>= 110lbs and a body mass index (BMI) \< 30. * Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder). * Do not have autoimmune diseases such as Hashimoto's thyroiditis, Myasthenia Gravis or Rheumatoid arthritis. * Report that they are able to perform daily self- care without assistance. * Report that they able to walk independently for at least 400 meters without assistance and without developing severe symptoms. * Report they are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs) or other severe symptoms. * Do not have cognitive impairment based on mental status screening tests and evaluations and in the absence of any drug treatment. * Do not have a history of cardiovascular disease or cerebrovascular disease including angina (requiring treatment), myocardial infarction, congestive heart failure, uncontrolled hypertension, pacemaker, stroke, or transient ischemic attacks (TIA). * Do not have a history of diabetes (requiring any medical treatment other than diet and exercise) and their fasting Glucose is \<126 mg/dL. * Do not have active (any activity in the last 10 years) cancer, except for locally limited squamous and basal cell cancer. * Do not have clinically significant hormonal dysfunction (Self-reported or laboratory values out of range. Mild hypothyroidism in participants over 60 is not considered exclusion). * Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and/or cognitive function). * Do not have a history of kidney or liver disease (associated with reduced kidney or liver function). * Do not have a history of severe gastrointestinal (G.I.) diseases, with symptoms or requiring chronic treatment such as gastroesophageal reflux disease (GERD), Crohn s disease or ulcerative colitis. * Do not have a history of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use. * Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and/or chronic pain). * Do not have a history of severe psychiatric conditions associated with behavioral problems or requiring absolute and continuous need for medical treatment. * Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and/or proton pump inhibitors, or pain medications. * Do not have a medical condition that requires the use of chronic anticoagulant medication such as Coumadin, heparin, or antiplatelet agents other than low dose aspirin. * Do not have important sensory deficits (legally blind and/or any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent). * Are able to read and speak English. * Are able to understand the study risks and procedures, and consent to participate in the study. * Not currently pregnant or a nursing mother. * Do not currently smoke/vape and have not done so in the past 3 months. * Veins are adequate for cytapheresis. * No current illness that as judged by the study physician substantially increases the risks associated with cytapheresis (active infections, allergies, etc.). * No history of allergy to acid- citrate- dextrose (ACD) anticoagulant. * No history of an active bleeding disorder such as hemophilia or Von Willebrand disease. * No history of seizures within the last 3 months. * No history of Lyme disease, unless six weeks' post treatment and no new symptoms, of Chagas disease, Babesiosis, or Leishmanias. * Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form. * Do not have hip or knee replacements or other medical conditions that prevent 3TMRI research scans from being performed. INCLUSION CRITERIA for the Non-Healthy-or-Frail and Frail groups: * Age \>= 20 years of age in the NHF group. * Age \>= 50 years of age in the F group. * Are willing to return every 2 years for study visit procedures. * Agree to genetic (DNA/RNA) sample collection, analysis, and storage. * Have good venous access for blood sampling. * Weigh \>= 110lbs and a body mass index (BMI) \<= 35. * Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder). * Do not have important sensory deficits (legally blind and/or any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent). * Are able to read and speak English. * Are able to understand the study risks and procedures, and consent t
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
National Institute of Aging, Clinical Research Unit
Baltimore, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy